Patheon Scientist Dr. Marshall Crew Named to Medicine Maker Power List 2015
Patheon, a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma sectors, today announced that Dr. Marshall Crew, vice president, global PDS scientific excellence, has been named one of the top 100 most influential people in drug development and manufacture by the publication The Medicine Maker.
Dr. Crew, an elite scientist and expert in low-solubility drug formulation, was previously CEO and founder of Agere Pharmaceuticals, a CDMO specializing in oral bioavailability of insoluble molecules that was recently acquired by Patheon. Dr. Crew’s career has been devoted to improving the delivery of poorly soluble drugs through innovation and technology. He has close to 30 patents and patent applications filed under his name.
“It is an honor to be included among such an accomplished group,” Dr. Crew said. “As a community, I’m optimistic that we will see many more advances realized by these accomplished scientists, engineers and healthcare professionals, who are working relentlessly toward driving positive change for the critical needs of patients.”
UK-based The Medicine Maker is a monthly publication with a focus on clinical, regulatory, development and manufacturing fields for biopharmaceuticals. The publication’s readers nominate individuals to the annual Power List, which is selected and ranked by an independent jury.
Patheon Media Relations
Tel: +1 (919) 210-0986
Patheon, a business unit of DPx Holdings B.V., delivers a combination of unrivaled quality, reliability and compliance, with a reputation for scientific and technical excellence to customers in the pharmaceutical and biopharma sector. A leading global provider with more than 8,000 employees worldwide, Patheon has a comprehensive set of solutions to help customers of all sizes satisfy complex development and manufacturing needs at any stage of the pharmaceutical development cycle. For more information, visit http://www.patheon.com.